Investigators from Eli Lilly and Company Zero in on Type 2 Diabetes [Tirzepatide Improved Health-related Quality of Life Compared With Insulin Lispro In Basal Insulin-treated Adults With Type 2 Diabetes and Inadequate Glycaemic Control: a ...]

MLA

“Investigators from Eli Lilly and Company Zero in on Type 2 Diabetes [Tirzepatide Improved Health-Related Quality of Life Compared With Insulin Lispro In Basal Insulin-Treated Adults With Type 2 Diabetes and Inadequate Glycaemic Control: A ...].” Obesity, Fitness & Wellness Week, Aug. 2024, p. 104. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.805225359&authtype=sso&custid=ns315887.

APA

Investigators from Eli Lilly and Company Zero in on Type 2 Diabetes [Tirzepatide Improved Health-related Quality of Life Compared With Insulin Lispro In Basal Insulin-treated Adults With Type 2 Diabetes and Inadequate Glycaemic Control: a ...]. (2024, August 24). Obesity, Fitness & Wellness Week, 104.

Chicago

Obesity, Fitness & Wellness Week. 2024. “Investigators from Eli Lilly and Company Zero in on Type 2 Diabetes [Tirzepatide Improved Health-Related Quality of Life Compared With Insulin Lispro In Basal Insulin-Treated Adults With Type 2 Diabetes and Inadequate Glycaemic Control: A ...],” August 24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.805225359&authtype=sso&custid=ns315887.